Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (vol 393, pg 143, 2019)

被引：0
|
作者：
Cahn, P.
Madero, J. S.
Arribas, J. R.
机构：
来源：
LANCET | 2019年 / 393卷 / 10167期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [21] Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
    Raffi, Francois
    Jaeger, Hans
    Quiros-Roldan, Eugenia
    Albrecht, Helmut
    Belonosova, Elena
    Gatell, Jose M.
    Baril, Jean-Guy
    Domingo, Pere
    Brennan, Care
    Almond, Steve
    Min, Sherene
    LANCET INFECTIOUS DISEASES, 2013, 13 (11): : 927 - 935
  • [22] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection-96-week results from the GEMINI studies
    Cahn, P.
    Sierra-Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C. -C.
    Rockstroh, J.
    Girard, P. -M.
    Sievers, J.
    Man, C.
    Urbaityte, R.
    Underwood, M.
    Tenorio, A. -R.
    Pappa, K.
    Wynne, B.
    Gartland, M.
    Aboud, M.
    van Wyk, J.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 103 - 103
  • [23] Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
    Gallant, Joel
    Lazzarin, Adriano
    Mills, Anthony
    Orkin, Chloe
    Podzamczer, Daniel
    Tebas, Pablo
    Girard, Pierre-Marie
    Brar, Indira
    Daar, Eric S.
    Wohl, David
    Rockstroh, Juergen
    Wei, Xuelian
    Custodio, Joseph
    White, Kirsten
    Martin, Hal
    Cheng, Andrew
    Quirk, Erin
    LANCET, 2017, 390 (10107): : 2063 - 2072
  • [24] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
    Orrell, Catherine
    Hagins, Debbie P.
    Belonosova, Elena
    Porteiro, Norma
    Walmsley, Sharon
    Falco, Vicenc
    Man, Choy Y.
    Aylott, Alicia
    Buchanan, Ann M.
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kimberly Y.
    LANCET HIV, 2017, 4 (12): : E536 - E546
  • [25] Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferioritytrial
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Koenig, Ellen
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Zhang, Fujie
    Rahman, Sophia
    D'Antoni, Michelle L.
    Wang, Hongyuan
    Hindman, Jason T.
    Martin, Hal
    Baeten, Jared M.
    Li, Tiasheng
    LANCET HIV, 2023, 10 (10): : E640 - E652
  • [26] Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Sax, Paul E.
    Pozniak, Anton
    Montes, M. Luisa
    Koenig, Ellen
    DeJesus, Edwin
    Stellbrink, Hans-Juergen
    Antinori, Andrea
    Workowski, Kimberly
    Slim, Jihad
    Reynes, Jacques
    Garner, Will
    Custodio, Joseph
    White, Kirsten
    SenGupta, Devi
    Cheng, Andrew
    Quirk, Erin
    LANCET, 2017, 390 (10107): : 2073 - 2082
  • [27] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    Cahn, Pedro
    Pozniak, Anton L.
    Mingrone, Horacio
    Shuldyakov, Andrey
    Brites, Carlos
    Andrade-Villanueva, Jaime F.
    Richmond, Gary
    Beltran Buendia, Carlos
    Fourie, Jan
    Ramgopal, Moti
    Hagins, Debbie
    Felizarta, Franco
    Madruga, Jose
    Reuter, Tania
    Newman, Tamara
    Small, Catherine B.
    Lombaard, John
    Grinsztejn, Beatriz
    Dorey, David
    Underwood, Mark
    Griffith, Sandy
    Min, Sherene
    LANCET, 2013, 382 (9893): : 700 - 708
  • [28] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
    DeJesus, Edwin
    Rockstroh, Juergen K.
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Yale, Kitty
    Szwarcberg, Javier
    White, Kirsten
    Cheng, Andrew K.
    Kearney, Brian P.
    LANCET, 2012, 379 (9835): : 2429 - 2438
  • [29] Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial (vol 13, pg 927, 2013)
    Raffi, F.
    Jaeger, H.
    Quiros-Roldan, E.
    LANCET INFECTIOUS DISEASES, 2014, 14 (08): : 675 - 675
  • [30] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study (vol 382, pg 700, 2013)
    Cahn, P.
    Pozniak, A. L.
    Mingrone, H.
    LANCET, 2014, 383 (9911): : 30 - 30
12345